Table 1 Overview of trials meeting systematic review inclusion criteria
From: Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
Author | Year | Population | Exp (N) | Cont (N) | Intervention | Drug dose | Follow-up (months) |
|---|---|---|---|---|---|---|---|
Akbulut | 2003 | HFrEF, EF ≤ 35%, NYHA III | 35 | 35 | spironolactone | 25 mg daily | 3 |
Boccanelli | 2009 | HFrEF, EF ≤ 45%, NYHA II | 215 | 223 | canrenone | 25 mg daily | 12 |
Chan | 2007 | HFrEF, EF < 40%, NYHA I–III | 23 | 25 | spironolactone | 25 mg daily | 12 |
Cicoira | 2002 | HFrEF, EF ≤ 45%, NYHA III | 54 | 52 | spironolactone | 25 mg daily | 12 |
Deswal | 2011 | HFpEF, EF ≥ 50%, NYHA II–III | 25 | 23 | eplerenone | 25 mg daily | 6 |
Edelmann | 2013 | HFpEF, EF ≥ 50%, NYHA II–III | 213 | 209 | spironolactone | 25 mg daily | 12 |
Edwards | 2009 | HFpEF, CKD stage 2–3 | 56 | 56 | spironolactone | 25 mg daily | 9 |
Zannad | 2011 | HFrEF, EF ≤ 35%, NYHA II | 1364 | 1373 | eplerenone | 25–50 mg daily | 21 |
Pitt | 2003 | MI + HFrEF, EF ≤ 40% | 3319 | 3313 | eplerenone | 25–50 mg daily | 16 |
Gao | 2007 | HFrEF, EF < 45%, NYHA II–IV | 58 | 58 | spironolactone | 20 mg daily | 6 |
Pitt | 2013 | HFrEF, EF ≤ 40%, CKD stage 2–3 | 63 | 65 | spironolactone | 25–50 mg daily | 1 |
Pitt | 1999 | HFrEF, EF < 35%, NYHA III–IV | 822 | 841 | spironolactone | 25–50 mg daily | 24 |
Pitt | 2014 | HFpEF, EF ≥ 45% | 1722 | 1723 | spironolactone | 15–45 mg daily | 40 |
Udelson | 2010 | HFrEF, EF ≤ 35% NYHA II–III | 117 | 109 | eplerenone | 50 mg daily | 9 |
Vizzardi | 2014 | HFrEF, EF < 40%, NYHA I–II | 65 | 65 | spironolactone | 25–100 mg daily | 44 |